Related by context. All words. (Click for frequent words.) 80 License Agreement 79 Distribution Agreement 71 Patent License Agreement 71 Licensing Deal 70 Collaboration Agreement 69 Supply Agreement 68 Licence Agreement 66 Reseller Agreement 65 Signs Licensing Agreement 65 Strategic Alliance 65 Exclusive Licensing Agreement 64 Licensing Agreements 64 Distributor Agreement 64 Distribution Pact 64 Distribution Agreements 63 Exclusive License 63 Signs License Agreement 63 Exclusive Distribution 63 Sign Licensing Agreement 62 Exclusive License Agreement 62 Teaming Agreement 62 Agreement 62 Signs Agreement 62 Commercialization Agreement 62 Licensing Pact 61 Announces License Agreement 61 License Pact 61 Sign License Agreement 61 License Agreements 61 Announces Licensing Agreement 61 Cross Licensing Agreement 61 Supply Agreements 61 Affiliation Agreement 61 Enters Agreement 60 Acquires Exclusive 60 Patent Licensing Agreement 60 Inks Agreement 60 Signs Licensing 60 License Option Agreement 59 Worldwide Licensing Agreement 59 Signs Agreements 59 Joint Venture Agreement 59 Announce Exclusive 59 Enter Into 59 Signs Exclusive 59 Sponsorship Agreement 59 Announce Licensing Agreement 59 Cross License Agreement 59 Enters Into Joint Venture 58 Distributorship Agreement 58 Enters Into Agreement 58 Forms Joint Venture 58 Agreements 58 Receives Patent 58 Announce Licensing 58 Inks Licensing Deal 58 Lease Agreement 58 Expand Relationship 58 Announce Agreement 57 Signs MOU 57 licensing agreements 57 Subsidiary Enters 57 Announce Joint Venture 57 Definitive Merger Agreement 57 Signs Contract 57 Enters Into 57 Reaches Agreement 57 Announces Definitive Agreement 57 Inks Pact 57 Announce License Agreement 57 Partnership Agreement 57 Announce Collaboration 57 Enters Into Licensing Agreement 57 Announce Collaboration Agreement 57 Enters Into Strategic 57 Acquisition Agreement 57 Expands Distribution 57 Purchase Agreement 57 Misonix Announces 56 Inks Deal 56 Announce Partnership 56 Signs Distribution 56 Secures Exclusive 56 Asset Purchase Agreement 56 Inks Exclusive 56 Enters Into License Agreement 56 Signs Deal 56 Secures Contract 56 Acacia Subsidiary Enters 56 Settles Patent Litigation 56 Cooperation Agreement 56 Enters Joint Venture 56 Master License Agreement 56 Representation Agreement 56 Files Patent Application 56 Establish Joint Venture 56 Forges Partnership 55 Strategic Relationship 55 Signs Long Term 55 Inks Deal With 55 Enters Into Partnership 55 Collaborates 55 Begins Shipment 55 Enters Strategic 55 Extend Partnership 55 Inks Distribution 55 Enters Into Exclusive 55 Obtains License 55 Expands Portfolio 55 Completes Reverse Merger 55 Extends Relationship 55 Extends Collaboration 55 Develop Novel 55 Signs Joint Venture 55 Signs Multi 55 Enters Into Letter 55 binding Letter 55 Executes Agreement 55 Settlement Agreement Regarding 55 Commercialize 55 Expand Collaboration 55 Inks Multi 55 Assignment Agreement 55 Settles Litigation 55 Achieves Milestone 55 Renews Agreement 54 Definitive Agreement 54 Milestone Payments 54 Secures Patent 54 Ink Deal 54 Completes Merger 54 Signs Pact 54 sublicense 54 Signs Option Agreement 54 Exercises Option 54 Announce Merger Agreement 54 Submits Application 54 Completes Asset 54 Acquire Assets 54 Polysilicon Supply Agreement 54 Mutually Agree 54 Finalizes Agreement 54 Awarded Patent 53 Amends Agreement 53 Option Agreement 53 Subsidiary Enters Into 53 Receives Milestone Payment 53 Patent Covering 53 Sublicense Agreement 53 Announces Termination 53 Enters Into Definitive 53 Cooperation Agreements 53 Patent Issued 53 Signs Lease 53 Joins Hands 53 Strikes Deal 53 Value Added Reseller Agreement 53 Receives Approval 53 Jointly Announce 53 Expands Relationship 53 Spins Off 53 Extend Collaboration 53 Signs LOI 53 Signs Binding Letter 53 Binding Agreement 53 Offtake Agreement 53 Reach Agreement 53 Closes Acquisition 53 Terminates Agreement 53 agreement 53 Rebrands 53 Extends Reach 53 Files Patent 53 Extends Contract 53 Announces Formation 53 Signs Memorandum 52 Signs Definitive Agreement 52 Secures Financing 52 Relaunches 52 Joins Forces 52 Collaborates With 52 Signs Letter 52 Delivers Next Generation 52 Enters Exclusive 52 Subsidiary Signs 52 Forms Strategic 52 Loan Agreement 52 Inks Licensing Agreement 52 Expands Presence 52 Confirms Commitment 52 Announces Intent 52 Extend Relationship 52 Inks Deals 52 Enters Into Definitive Agreement 52 Strategic Partnership 52 Jointly Develop 52 Achieves Significant 52 Strengthens Position 52 Signs Merger Agreement 52 Develop Next Generation 52 Obtains Exclusive License 52 Signs Definitive 52 Enters Negotiations 52 Strengthens Its 52 Commercializes 52 Announce Strategic 52 Transfer Agreement 52 Complete Merger 52 BioSante Pharmaceuticals Announces 52 Receives FDA Clearance 52 Completes Acquisition 52 Expands Scope 52 Settlement Agreement 52 Enters 52 Formal Option Agreement 52 Definitive Agreements 52 HSR Waiting Period 52 Awarded Contract 51 Hyperion Catalysis International 51 Termination Agreement 51 Terminates Merger Agreement 51 Subsidiary 51 Exclusivity Agreement 51 Wafer Supply 51 Restructures 51 Acquire Controlling Interest 51 Files IND 51 Announces Signing 51 Exclusive Licensee 51 Acquirer Company 51 Sponsorship Deal 51 FDA Clears 51 Completes Patient Enrollment 51 Initiates Phase II 51 Endorsement Deal 51 Taiho Pharmaceutical 51 Million Dollar Contract 51 Settle Litigation 51 Finalizes Acquisition 51 Inks LOI 51 Inks License 51 Announces Expansion 51 Strengthens Commitment 51 Terminates Contract 51 Expands Availability 51 Completes Financing 51 Continues Momentum 51 Begins Shipping 51 Closes Merger 51 Exclusive Licensing 51 Receives Orphan Drug Designation 51 Discontinues 51 Shareholders Approve Merger 51 Awarded Multi 51 Acquires Controlling Interest 51 Obtains Exclusive Rights 51 Granted Orphan Drug 51 LOI 51 Enters Into Settlement Agreement 51 Expands Internationally 51 Expands Relationship With 51 Broadens Its 51 Sign Definitive Agreement 51 Signs MoU 51 Milestone Payment 51 Expands Into 51 Announce Interoperability 51 Stock Purchase Agreement 51 Stockholders Approve Merger 51 Receives Order 51 Contract Renewal 51 Forges Strategic 51 Binding Letter 50 Introduces Breakthrough 50 Multimillion Dollar Contract 50 Report Analyzes 50 Strengthens Relationship 50 Negotiates 50 SpeBio joint venture 50 Contribution Agreement 50 Initiates Clinical Trial 50 Closes Financing 50 Announces FDA Clearance 50 Acquires 50 Inks Supply 50 Announces Issuance 50 Flagship Product 50 Files Registration Statement 50 Enters Into Long Term 50 Revitalizes 50 Expanding Presence 50 Announces Tentative Approval 50 Enter Into Definitive 50 Enters Into LOI 50 Completes Acquisitions 50 FDA Accepts 50 Patents Covering 50 Acacia Subsidiary 50 Signs Binding 50 Patent Dispute 50 Entered Into 50 Licenses Novel 50 Wins Approval 50 Relaunches Website 50 Continues Expansion 50 Combination Agreement 50 Finalize Agreement 50 Receives Funding 50 Announce Signing 50 Announces Definitive Merger 50 Announces Expanded 50 Signs Multiyear 50 Global Reseller Agreement 50 Reseller Partnership 50 Initiates Enrollment 50 Million Financing 50 Secures Long Term 50 Initiates Dosing 50 Obtains Patent 50 Codeshare Agreement 50 Licenses Patents 50 Arbitration Proceeding 50 Unveils Innovative 50 Enters Into Collaboration 50 Agreement SEDA 50 FDA Approves 50 Outsourcing Contract 50 Roaming Agreement 50 Patents Issued 50 Reaches Milestone 50 Share Purchase Agreement 50 Renews Contract 50 Official Licensee 50 Jointly Offer 50 Platform Enables 50 Settle Patent Dispute 50 Continues Commitment 50 Receives Notice 50 Completes Enrollment 50 Join Forces 50 Reacquires 50 Resolves Dispute 50 Patent Infringement Litigation 50 Letter Agreement 50 Becomes Exclusive 50 Handok Pharmaceuticals 50 Completes Transaction 50 Ink Pact 50 Announce Expanded 50 Therapeutic Competitors Report 50 Attains 50 Sublicense 50 Wins Contract 50 Patent Portfolio 50 Expands Offerings 50 Procures 50 Expands Capabilities 50 Completes Sale 50 Announce Groundbreaking 50 Acquires Assets 50 Derma Sciences Announces 50 Renews Partnership 50 Enters Into Distribution 49 Co Branded 49 Term Sheet 49 Drug Candidate 49 Expands 49 Settle Patent Litigation 49 Enters Into Agreements 49 Obtains 49 Receives Certification 49 Sign Definitive Merger 49 Finalizes 49 Terminate Agreement 49 Exclusive Distributor 49 Enrolls First 49 Announces Proposed Acquisition 49 Receives Confirmation 49 Successfully Launches 49 Merges 49 Biomarker Study 49 Signs LoI 49 Joint Venture 49 Announces Immediate Availability 49 Option Agreements 49 News Unternehmensnachrichten 49 DARA logo 49 FY# Loss Widens 49 Signs Purchase Agreement 49 Aligns 49 Patent Infringement Suit Against 49 Completes Merger With 49 Initiates Clinical 49 Seamless Integration 49 CRADA 49 Amalgamation Agreement 49 exclusive distributorship 49 Expands Reach 49 Broadens 49 Introduces Revolutionary 49 Announces Acquisition 49 Streamlines Operations 49 Launches Unique 49 Expand Presence 49 Receives Commitment 49 Patent Upheld 49 Receives Notification 49 Submits NDA 49 Earns Milestone Payment 49 Announces Initiation 49 Renews Multi 49 Scientists Develop 49 Updates Shareholders 49 Formalizes 49 Settle Patent Lawsuit 49 MorphoSys proprietary 49 Settles Patent Dispute 49 Terminate Merger Agreement 49 Study Validates 49 Withdraws Application 49 Forges Ahead 49 Registered Trademark 49 Establishes Joint Venture 49 Signs Reseller Agreement 49 Doubles Capacity 49 Agreement Reached 49 Amended Agreement 49 Announce Availability 49 Presents Preclinical Data 49 Seeks Approval 49 Finalizes Contract 49 FDA Okays 49 Important Milestone 49 Completes Private Placement 49 Aquires 49 Settles Dispute 49 Galderma SA 49 Announces Launch 49 Issued Patent 49 Revolutionizes 49 Million Contract 49 Website Launched 49 Anti CD# Antibody 49 Finalizes Joint Venture 49 Reaches Settlement Agreement 49 Receive Milestone Payment 49 Extends Tender Offer 49 Celebrates Opening 49 CollaRx GENTAMICIN SURGICAL IMPLANT 49 Expands Footprint 49 Norgine BV 49 Obtains Approval 49 Celebrates Successful 49 Equipment Deals 49 Therapeutic Competitors Companies 49 Subsidiary Acquires 49 Completes Purchase 49 Develops Innovative 49 Closes Sale 48 Acquire Majority Stake 48 Receives Tentative Approval 48 Previously Announced 48 Purchase Agreements 48 Patent Infringement Lawsuit Against 48 Announce Commencement 48 Conditional Approval 48 Expands Capacity 48 Presents Positive 48 Announces Private Placement 48 Enters Into Multi 48 agreements 48 Product Offerings 48 Jointly Launch 48 Announces Intention 48 Annouces 48 commercialize Dimebon 48 Collaborators Publish 48 Extends Relationship With 48 Acacia Subsidiary Acquires 48 Board Authorizes 48 Oral Calcitonin 48 Testosterone Gel 48 Q3 Loss Widens 48 Formal Agreement 48 Cavitation Technologies 48 Appoints Experienced 48 Announce Completion 48 Announces Affiliation 48 Announce Definitive Agreement 48 Amending Agreement 48 Changes Name 48 Inks Contract 48 Regains Full 48 Penetrates 48 Development Agreement CRADA 48 Modem Card 48 Orbital Successfully Launches 48 Flamel Technologies Announces 48 Terminates 48 Executes Definitive Agreement 48 Gets FDA Clearance 48 Trademark License Agreement 48 Settle Patent 48 HuCAL PLATINUM R 48 Awarded Patents 48 Announces Successful 48 Taglich Brothers Initiates Coverage 48 Joint Venture Agreements 48 Receives Fast Track 48 Receives CE Marking 48 Achieves ISO #:# Certification [002] 48 Acquistion 48 Molecular Diagnostic Test 48 Initiates Clinical Trials 48 Milestone Achieved 48 Confidentiality Agreement 48 Q2 Loss Narrows 48 Q3 Loss Narrows 48 Non Binding Letter 48 Achieves Certification 48 Pact 48 Completes Transition 48 Amend Merger Agreement 48 Reaches Settlement 48 Finalizes Deal 48 MOU 48 Receives Favorable 48 Receives Clearance 48 Obtains Exclusive 48 Officially Launches 48 Entry Into 48 Renews Exclusive 48 Settles Patent Suit 48 Unveils Revolutionary 48 Awarded Contract Extension 48 Articulation Agreement 48 Contract Extension 48 Momentum Continues 48 Diversifies 48 Unveils Newest 48 Progresses 48 definitive agreement 48 Divests 48 Multi Billion Dollar 48 Enters Into Negotiations 48 Purchase Option Agreement 48 Monoclonal Antibody 48 Financing Agreements 48 Settle Lawsuit 48 Mylan Receives Approval 48 Signs Non Binding 48 Leading Provider 48 Acquires Remaining Interest 48 Amplifies 48 CysDisplay R 48 BioElectronics Corporation Announces 48 Completes Previously Announced 48 ACACIA ACAC TECH 48 Infringement Case 48 Novartis Novo Nordisk 48 Fortifies 48 Receives Conditional 48 Long Term Relationship 48 Patent Suit 48 Q1 Loss Widens 48 Receives Regulatory 48 Renews Sponsorship 48 SRL Biovail 48 Dendritic Nanotechnologies Inc. 48 Identifies Potential 48 Announces Enhancements 48 Reaches Pact 48 Framework Agreement 48 Present Preclinical Data 48 Receives Orphan Drug 48 Could Revolutionize 48 Offers Affordable 48 Completes Recapitalization 48 Files Patents 48 Earns Certification 48 Announce Settlement 48 Monetizes 48 Executes Letter 48 Named Exclusive Distributor 48 Unveils Expanded 48 Buys Majority Stake 48 Shareholders Approve Acquisition 48 Announces Sponsorship 48 Closes Previously Announced 48 Expand Into 48 Consummates 48 Deepens Commitment 48 Strengthens Balance Sheet 48 Submits Proposal 48 TM MMP Portfolio 48 Complies 48 Awarded Contracts 48 Unveils Breakthrough 48 Secures Additional 47 Announces Shareholder Approval 47 Extends Commitment 47 Gets Approval 47 agreementwith 47 Latest Addition 47 Successfully Tests 47 Restructures Debt 47 Restructures Operations 47 Introduces Enhanced 47 Marks Milestone 47 Awarded GSA Schedule 47 Establishes Strategic 47 Announces Proposed 47 Q2 Loss Widens 47 Announces Receipt 47 Successfully Complete 47 sub licensable 47 Concludes Acquisition 47 Deliver Integrated 47 Inks Long Term 47 Closes Private Placement 47 AnaSpec Introduces 47 TRANSDUR ™ 47 Completes Reorganization 47 Pacts 47 Exploring Strategic Alternatives 47 Dramatically Expands 47 Regains Compliance 47 Announce Intention 47 Signs Definitive Agreements 47 commercialize telaprevir 47 Explore Strategic Alternatives 47 Settle Dispute 47 Demonstrates Commitment 47 Lease Agreements 47 Completes Tender Offer 47 Patent Infringement 47 FDA Approval 47 Furthers Commitment 47 Significantly Enhances 47 Successfully Integrates 47 Completes Integration 47 Announces Commencement 47 Waiver Agreement 47 sublicensed 47 Acquires Stake 47 Announces Availability 47 Furthers 47 Spins Out 47 Patent Infringement Suit 47 Gene Expression Analysis 47 Unveils Next Generation 47 Psoriasis Drug 47 Nippon Kayaku 47 Positions Itself 47 Expansion Into 47 Zor Pharmaceuticals 47 Q1 Loss Narrows 47 Merge Creating 47 Finalizes Merger 47 Launches Innovative 47 Announces Organizational Changes 47 Successfully Concludes 47 Newly Formed 47 Recombinant Protein 47 Introduces Next Generation 47 GenWay Biotech 47 Realigns 47 nonexclusive license 47 Pharmaceuticals Initiates 47 Inks MOU 47 Provides Updates 47 Introduces Powerful 47 Rapidly Expanding 47 Milestone Payment From 47 Receives SFDA Approval 47 Secures Funding 47 Launches Groundbreaking 47 Commences Operations 47 Successful Completion 47 Announces Closing 47 Acquires Majority 47 wholly owned subsidiary 47 Announces Reverse Merger 47 Expands Globally 47 Renegotiates 47 Momentum Grows 47 Systemic Delivery 47 Provides Shareholder 47 Sign Pact 47 Files Shelf Registration Statement 47 Completes Buyout 47 Miraculins Announces 47 VIVITROL ® 47 commercialize Aganocides 47 Partners Invests 47 Successfully Completes Tender Offer 47 acne impetigo 47 Significantly Reduces 47 Snaps Up 47 Provides Update Regarding 47 Expands Coverage 47 Reach Settlement 47 Ventures Invests 47 Announces Consummation 47 BIOLASE Announces 47 Reports Receipt 47 Further Strengthens 47 RNAi Therapeutics 47 Launches Redesigned Website 47 Announce Early Termination 47 Wins Summary Judgment 47 Immunomedics Announces 47 Provide Enhanced 47 contain Totally Degradable 47 Ceases 47 Researchers Develop 47 Acquires Majority Stake 47 Infringed 47 Interconnection Agreement 47 Proves Successful 47 AllPennyStocks.com Spotlights 47 Revolutionises 47 Earns Certified Partner 47 Starts Shipping 47 Completes Initial 47 Launches Enhanced 47 Pinnacle Digest Looking 47 Be Acquired 47 Leases 47 Achieves Milestones 47 Stockholders Approve Acquisition 47 Widely Available 47 Breaks Ground 47 Securities Purchase Agreement 47 Submits Bid 47 Multiyear Agreement 47 Announces Successful Completion 47 Receives NASDAQ 47 Patent Infringement Case 47 Patent Infringement Action 47 Amends Terms 47 Advanced Colorectal Cancer 47 Achieves Record 47 Loramyc ™ 47 Develop Innovative 47 Deliver Innovative 47 Enters Into Merger Agreement 47 Receives Favorable Ruling 47 Significant Milestones 47 Multiyear Deal 47 License Application 47 Subsidiary Awarded 46 Launches Revamped Website 46 Extends Offer 46 Completes Installation 46 Introduces Innovative 46 Osiris retains 46 Voluntarily Withdraw 46 JAK2 Inhibitor 46 Accelerates Expansion 46 Furthers Its 46 Awarded GSA 46 Makes Strides 46 Achieves Prestigious 46 Patent Infringement Lawsuit 46 Launches Next Generation 46 Expanded Indication 46 Delivers Innovative 46 Has Entered 46 Settles Patent Infringement Lawsuit 46 Provide Comprehensive 46 Announces Completion 46 Unveils Latest 46 Expert Joins 46 Unveils Powerful 46 Announces Reseller Agreement 46 Reaffirms Commitment 46 Announces Discontinuation 46 Deliver Powerful 46 Transdermal Drug 46 Announces Divestiture 46 Finalize Joint Venture 46 Subsidiary Receives 46 Reach Settlement Agreement 46 Forbearance Agreement 46 Announces Spin Off 46 Q4 Loss Widens 46 Visual Voicemail patent 46 Hits Milestone 46 Forges Alliance 46 Announces Stockholder Approval 46 Concludes Successful 46 Receives Notice From 46 Completes Divestiture 46 Successfully Completed 46 Lescarden 46 Hextend R 46 ELADUR TM 46 Receives Conditional Approval 46 File Transfers 46 Million Private Placement 46 Reduces Debt 46 Solution Helps 46 Receives Positive 46 Completes Purchase Of 46 Releases Latest Version 46 Newly Acquired 46 Collaboration 46 Small Molecule 46 Subscription Agreement 46 Becomes Largest 46 Debuts Next Generation 46 Submits IND 46 Definitive Option Agreement 46 Strengthens Presence 46 Renews 46 Builds Momentum 46 Report Examines 46 Wholly Owned Subsidiary 46 Key Milestones 46 Contract 46 Selects Juniper Networks 46 Submits Biologics License Application 46 Settles Charges 46 :/ finance.yahoo.com q 46 JV SpeBio 46 Gobbles Up 46 Announces Rebranding 46 Nasdaq XTLB 46 Outlines Strategy 46 Increases Ownership 46 Expands Commitment 46 & Sullivan Recognizes 46 Multi Faceted 46 Becomes Authorized 46 Interoperate 46 Integrates 46 Releases Upgraded 46 Sees Continued Growth 46 sublicenses 46 Expansion Continues 46 Releases Next Generation 46 Code# [001] 46 Obtains FDA 46 Becomes Newest 46 DayTradersDigest.com Profiles 46 Introduces Unique 46 Inc Therapeutic Competitors 46 Announces Addition 46 Seikagaku Corporation 46 FY# Loss Narrows 46 Nears Deal 46 Manufacturer Selects 46 Enters Option Agreement 46 Timolol ophthalmic solution 46 Announces Debt Settlement 46 Sensipar R 46 Successfully Tested 46 Announces Granting 46 Portfolio License 46 Long Term Lease 46 Exclusivity Period 46 Ratifies 46 Asset Swap 46 Markets Examine 46 Patent Lawsuit 46 Files Patent Infringement Lawsuit 46 Files Patent Infringement 46 Taro Receives 46 NMP# ® 46 Successfully Completes 46 Gentamicin Surgical Implant 46 Intellectual Property Portfolio 46 Countersues 46 IIROC Resume 46 Clears Path 46 Streamlines 46 Nears Completion 46 Enlarges 46 Patent Broadly Covering 46 Standstill Agreement 46 Repositions 46 IIROC Halt 46 Trademark Infringement 46 Participation Agreement 46 Software Simplifies 46 Secures 46 Increases Commitment 46 Significantly Expands 46 Merger Agreement 46 Nanophase Announces 46 Files Suit Against 46 Creates Unique 46 Renews Long Term 46 Engages CHF Investor Relations 46 Inc. OTCBB BLEW 46 Begins Rollout 46 Commence Trading 46 Largest Ever 46 Distinguishes 46 Increases Presence 46 Trade Pact 46 Patent Lawsuit Against 46 Injunction Against 46 Enhances User Experience 46 S2 Therapeutics 46 Settlement Reached 46 Certifies 46 Presents Positive Preclinical 46 Pending Acquisition 46 Generic Version 46 Improves Efficiency 46 Agensys subsidiary 46 Deliver Enhanced 46 exclusive licensee 46 Successfully Demonstrates 46 Patent Disputes 46 GRAS Status 46 Acquire 46 Subsidiary Awarded Contract 46 subsidiary Biovail Laboratories 46 Generic Versions 46 Sign Reseller Agreement 46 Clearford Announces 46 MarketResearch.com Announces 46 Announces Definitive Agreements 46 Study Identifies 46 Autodesk Completes Acquisition 46 Appoints Seasoned 46 FDA Approvals 46 Finalises 46 Restate Financials 46 Deliver Comprehensive 46 Updates Status 46 #.#.# Meldung [001] 45 Tumor Targeting 45 Moves Forward 45 Closes Acquisition Of 45 Develops Novel 45 commercializing Loramyc ® 45 FDA Clearance 45 Receives Approval From 45 Nasdaq Listing Requirements 45 commercialize Aganocide compounds 45 Fortical ® 45 Inc. OTCBB BOCL 45 Contracts Awarded 45 Clean Diesel patented 45 POTELLIGENT R Technology 45 Makes Inroads 45 sublicensing 45 Legal Dispute 45 Extends Presence 45 Fixed Dose Combination 45 Integra LifeSciences Announces 45 Contracts Totaling 45 Announces Additions 45 Controlling Interest 45 Chooses 45 Offers Unprecedented 45 Multimillion Dollar 45 Launches Website 45 Purchase Order 45 OPGX 45 Square Enix Eidos 45 Receives Tentative FDA 45 Name Change 45 Nasdaq HALO 45 Withdraws Offer 45 Announces 45 Kinase Inhibitors 45 Collaborate 45 Releases Latest 45 Achieves Cisco 45 Announce Breakthrough 45 Officially Opens 45 Provides Unprecedented 45 Successfully Closes 45 Drug Shows Promise 45 Accepted Into 45 High Growth Forecasted 45 Search Capabilities 45 Differentiates 45 Establishes Subsidiary 45 Completes Implementation 45 Renews Relationship 45 Reports Positive 45 Successful Conclusion 45 Cooperates 45 GTC NASDAQ GTCB 45 Rheumatoid Arthritis Drug 45 Franchise Agreements 45 Strengthens Ties 45 Cenomed 45 Extend Reach 45 Merge Healthcare Announces 45 Boosts Capacity 45 www.shamrockstocks.com About 45 PerkinElmer Acquires